**National Syndromic Surveillance Program**

**Supporting Statement Section B**

**OMB Control Number 0920-0824**

**July 8, 2022**

**Program Contact**

**Umed A. Ajani**

Associate Director for Science, Division of Health Informatics and Surveillance

Center for Surveillance, Epidemiology and Laboratory Services

Centers for Disease Control and Prevention

Phone: 404-498-0258

E-mail: UAjani@cdc.gov

**National Syndromic Surveillance Program - Request for Revision**

**Table of Contents**

**Section**

**B. Statistical Methods**

1. Respondent Universe and Sampling Methods

2. Procedures for the Collection of Information

3. Methods to Maximize Response Rates and Deal with No response

4. Tests of Procedures or Methods to be Undertaken

5. Individuals Consulted on Statistical Aspects and Individuals Collecting and/or Analyzing Data

**National Syndromic Surveillance Program Supporting Statement**

**B. Statistical Design and Data Collection Procedures**

There are no statistical methods used for onboarding, registration, or data sharing permissions information collection. Information for onboarding and registration consists of administrative data that are not summarized statistically (**Statement A**). Although onboarding and registration data may be used to identify numbers of sites and users of the BioSense Platform, these activities do not involve any complex statistical methods.

**B1. Respondent Universe and Sampling Methods**

The respondent universe for participating sites has not changed and consists of state, local, and territorial public health departments. Currently, there are 70 sites participating from state, local and territorial public health departments. Participation is completely voluntary.

The respondent universe for registration information collection has not changed and consists of potential users of the BioSense Platform from participating state, local, and territorial public health departments. No sampling is used and registration is completely voluntary.

**B2. Procedures for the Collection of Information**

All onboarding data, registration data, and data sharing permissions are collected from state, local, and territorial public health departments through modules on the BioSense Platform Access Management Center (AMC).

**B3. Methods to Maximize Response Rates and Deal with No response**

CDC and the Council of State and Territorial Epidemiologists (CSTE) collaborate to reach out and provide information to the public health community about the opportunity to participate in NSSP.

**B4. Tests of Procedures or Methods to be Undertaken**

No pilot testing of data collection procedures or methods will be undertaken.

**B5. Individuals Consulted on Statistical Aspects and Individuals Collecting and/or Analyzing Data**

 The primary group with which CDC consults is The NSSP Community of Practice (CoP).